ORAGENICS INC 8-K

What Happened
Oragenics, Inc. (OGEN) filed an 8‑K on April 13, 2026, and issued a press release announcing that the first patient has been dosed in its ongoing Phase IIa clinical trial in Australia. The trial is evaluating ONP‑002, the company’s lead candidate for the treatment of concussion and mild traumatic brain injury (mTBI). The press release was attached to the filing as Exhibit 99.1.

Key Details

• Filing date: April 13, 2026 (Form 8‑K, Item 8.01 – Other Events).
• Milestone: First patient dosed in the Phase IIa clinical trial in Australia.
• Drug: ONP‑002, Oragenics’ lead candidate targeting concussion and mTBI.
• Disclosure: Announcement made via press release (Exhibit 99.1) included with the 8‑K.

Why It Matters
This is a development milestone for Oragenics’ clinical program: dosing the first patient advances ONP‑002 from earlier studies into a mid‑stage (Phase IIa) trial, which may generate initial safety and efficacy data for concussion/mTBI. The filing does not include trial results, financial metrics, or changes in management; it simply reports the dosing event. Investors should view this as a program progress update and watch for future clinical data releases or regulatory updates.